echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > "Science" sub-published secret: It is a carcinogen but can effectively inhibit the spread of cancer cells

    "Science" sub-published secret: It is a carcinogen but can effectively inhibit the spread of cancer cells

    • Last Update: 2021-08-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    In recent years, immunotherapy has shown great promise, but in fact, the effect of this therapy on many types of cancer is not satisfactory, especially for "cold tumors", which is basically ineffective, mainly due to the amount of cancer cell mutations in the cold tumor environment.


    Recently, this conjecture has been verified.


    In order to determine the effect of exposed carcinogens on "cold tumor" breast cancer, the researchers constructed a mature spontaneous breast cancer mouse model, and used the carcinogen "2,2-dimethylolbutyric acid (DMBA)" to stimulate small In mice, the study found that despite the faster growth of tumors in mice stimulated by DMBA, the phenomenon of cancer metastasis was significantly reduced, indicating that breast cancer metastasis under DMBA exposure was effectively blocked


    Breast cancer metastasis in DMBA-exposed animals is blocked

    As we all know, CD8 + T cells are a subgroup of T lymphocytes, which secrete various cytokines to participate in immune activities, have a killing effect on tumor cells and other antigenic substances, and can form an important line of defense for the body's anti-tumor immunity with natural killer cells


    Therefore, in order to verify whether T cells can block breast cancer metastasis exposed to DMBA, the researchers analyzed the infiltrating T cells in primary breast cancer tissues stimulated by DMBA and found that a large number of T cells gathered near breast tumors.


    Blocking breast cancer metastasis in DMBA-treated PyMT mice requires CD8 + T cells

    In recent years, because the chemokine CCL21 and its receptor CCR7 play an important role in the selective and specific metastasis of tumor cells, they have gradually become a new target for anti-tumor metastasis drug therapy, and various CCL21-based immunotherapy strategies continue to emerge.


    Preliminary studies have found that CCL21 can promote T cells to participate in lymphocyte homing and strongly drive T lymphocytes


    CCL21 inhibits breast tumor growth by inducing anti-tumor CD8 + T cell immunity in vivo

    In fact, this unique concept of suppressing cancer has been reflected in the treatment of lung cancer as early as possible


    This is mainly due to the fact that the number of genetic mutations in smoking lung cancer patients is more than 10 times that of non-smokers, and the more genetic mutations, the more immune cells can recognize tumor cells and the better its killing effect


    Note: The original text has been deleted

    Reference materials:

    [1]https://advances.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.